Preclinical Studies of Narmafotinib in Pancreatic Cancer Published Online
Amplia Therapeutics Limited announced that a scientific manuscript detailing preclinical studies on narmafotinib, its FAK inhibitor drug candidate for pancreatic cancer, is now available online. The research conducted by Professor Paul Timpson and colleagues at the Garvan Institute of Medical Research highlights multiple mechanisms through which narmafotinib may improve outcomes in pancreatic cancer patients. Key findings include a reduction in tumour fibrosis, enhanced anti-tumour activity when combined with chemotherapy, reduced metastatic spread, and downregulation of genes linked to chemotherapy resistance. These results support the biological rationale for combining narmafotinib with existing therapies and strengthen its clinical development potential. The publication is part of Amplia's ongoing efforts in developing treatments for fibrotic cancers like pancreatic cancer. Dr Chris Burns, CEO of Amplia, emphasized that these findings represent one of the most comprehensive preclinical evaluations to date.